Cargando…

Changes in Antithrombotic Therapy Over Time and Durability of a Prasugrel WOEST-Like Regimen for Percutaneous Coronary Intervention Patients With Atrial Fibrillation ― Post Hoc Analysis of the PENDULUM Mono and PENDULUM Registries ―

Background: Previously published randomized atrial fibrillation (AF) percutaneous coronary intervention (PCI) trials have demonstrated the safety and efficacy of a WOEST-like regimen (oral anticoagulant [OAC] plus P2Y(12) inhibitor) in patients with AF PCI within 1 year. However, the efficacy of thi...

Descripción completa

Detalles Bibliográficos
Autores principales: Nakao, Koichi, Kadota, Kazushige, Nakagawa, Yoshihisa, Shite, Junya, Yokoi, Hiroyoshi, Kozuma, Ken, Tanabe, Kengo, Akasaka, Takashi, Shinke, Toshiro, Ueno, Takafumi, Hirayama, Atsushi, Uemura, Shiro, Harada, Atsushi, Kuroda, Takeshi, Takita, Atsushi, Iijima, Raisuke, Murakami, Yoshitaka, Saito, Shigeru, Nakamura, Masato
Formato: Online Artículo Texto
Lenguaje:English
Publicado: The Japanese Circulation Society 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9072101/
https://www.ncbi.nlm.nih.gov/pubmed/35600719
http://dx.doi.org/10.1253/circrep.CR-22-0032
_version_ 1784700982746152960
author Nakao, Koichi
Kadota, Kazushige
Nakagawa, Yoshihisa
Shite, Junya
Yokoi, Hiroyoshi
Kozuma, Ken
Tanabe, Kengo
Akasaka, Takashi
Shinke, Toshiro
Ueno, Takafumi
Hirayama, Atsushi
Uemura, Shiro
Harada, Atsushi
Kuroda, Takeshi
Takita, Atsushi
Iijima, Raisuke
Murakami, Yoshitaka
Saito, Shigeru
Nakamura, Masato
author_facet Nakao, Koichi
Kadota, Kazushige
Nakagawa, Yoshihisa
Shite, Junya
Yokoi, Hiroyoshi
Kozuma, Ken
Tanabe, Kengo
Akasaka, Takashi
Shinke, Toshiro
Ueno, Takafumi
Hirayama, Atsushi
Uemura, Shiro
Harada, Atsushi
Kuroda, Takeshi
Takita, Atsushi
Iijima, Raisuke
Murakami, Yoshitaka
Saito, Shigeru
Nakamura, Masato
author_sort Nakao, Koichi
collection PubMed
description Background: Previously published randomized atrial fibrillation (AF) percutaneous coronary intervention (PCI) trials have demonstrated the safety and efficacy of a WOEST-like regimen (oral anticoagulant [OAC] plus P2Y(12) inhibitor) in patients with AF PCI within 1 year. However, the efficacy of this regimen in real-world practice has not been fully confirmed, especially the efficacy of the WOEST-like regimen using the approved dose of prasugrel in Japan. Methods and Results: This post hoc analysis included 186 and 220 patients from the PENDULUM mono and PENDULUM registries, respectively. Endpoints were the cumulative incidences of clinically relevant bleeding (CRB) and major adverse cardiac and cerebrovascular events (MACCE) at 12 months after PCI. Differences in the enrollment period led to an increase in OAC prescriptions (from 64.7% to 81.2%) and a reduction in the median duration of triple antithrombotic therapy (from 203.0 to 32.0 days) in the PENDULUM vs. PENDULUM mono registries, respectively. After adjustment by the inverse probability of treatment method, in patients with OAC, PENDULUM mono AF significantly reduced CRB without increasing MACCE compared with PENDULUM AF. Conclusions: A WOEST-like regimen with prasugrel may reduce CRB, without increasing MACCE, in Japanese patients with AF and high bleeding risk undergoing PCI.
format Online
Article
Text
id pubmed-9072101
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher The Japanese Circulation Society
record_format MEDLINE/PubMed
spelling pubmed-90721012022-05-21 Changes in Antithrombotic Therapy Over Time and Durability of a Prasugrel WOEST-Like Regimen for Percutaneous Coronary Intervention Patients With Atrial Fibrillation ― Post Hoc Analysis of the PENDULUM Mono and PENDULUM Registries ― Nakao, Koichi Kadota, Kazushige Nakagawa, Yoshihisa Shite, Junya Yokoi, Hiroyoshi Kozuma, Ken Tanabe, Kengo Akasaka, Takashi Shinke, Toshiro Ueno, Takafumi Hirayama, Atsushi Uemura, Shiro Harada, Atsushi Kuroda, Takeshi Takita, Atsushi Iijima, Raisuke Murakami, Yoshitaka Saito, Shigeru Nakamura, Masato Circ Rep Original article Background: Previously published randomized atrial fibrillation (AF) percutaneous coronary intervention (PCI) trials have demonstrated the safety and efficacy of a WOEST-like regimen (oral anticoagulant [OAC] plus P2Y(12) inhibitor) in patients with AF PCI within 1 year. However, the efficacy of this regimen in real-world practice has not been fully confirmed, especially the efficacy of the WOEST-like regimen using the approved dose of prasugrel in Japan. Methods and Results: This post hoc analysis included 186 and 220 patients from the PENDULUM mono and PENDULUM registries, respectively. Endpoints were the cumulative incidences of clinically relevant bleeding (CRB) and major adverse cardiac and cerebrovascular events (MACCE) at 12 months after PCI. Differences in the enrollment period led to an increase in OAC prescriptions (from 64.7% to 81.2%) and a reduction in the median duration of triple antithrombotic therapy (from 203.0 to 32.0 days) in the PENDULUM vs. PENDULUM mono registries, respectively. After adjustment by the inverse probability of treatment method, in patients with OAC, PENDULUM mono AF significantly reduced CRB without increasing MACCE compared with PENDULUM AF. Conclusions: A WOEST-like regimen with prasugrel may reduce CRB, without increasing MACCE, in Japanese patients with AF and high bleeding risk undergoing PCI. The Japanese Circulation Society 2022-04-21 /pmc/articles/PMC9072101/ /pubmed/35600719 http://dx.doi.org/10.1253/circrep.CR-22-0032 Text en Copyright © 2022, THE JAPANESE CIRCULATION SOCIETY https://creativecommons.org/licenses/by-nc-nd/4.0/This article is licensed under a Creative Commons [Attribution-NonCommercial-NoDerivatives 4.0 International] license.
spellingShingle Original article
Nakao, Koichi
Kadota, Kazushige
Nakagawa, Yoshihisa
Shite, Junya
Yokoi, Hiroyoshi
Kozuma, Ken
Tanabe, Kengo
Akasaka, Takashi
Shinke, Toshiro
Ueno, Takafumi
Hirayama, Atsushi
Uemura, Shiro
Harada, Atsushi
Kuroda, Takeshi
Takita, Atsushi
Iijima, Raisuke
Murakami, Yoshitaka
Saito, Shigeru
Nakamura, Masato
Changes in Antithrombotic Therapy Over Time and Durability of a Prasugrel WOEST-Like Regimen for Percutaneous Coronary Intervention Patients With Atrial Fibrillation ― Post Hoc Analysis of the PENDULUM Mono and PENDULUM Registries ―
title Changes in Antithrombotic Therapy Over Time and Durability of a Prasugrel WOEST-Like Regimen for Percutaneous Coronary Intervention Patients With Atrial Fibrillation ― Post Hoc Analysis of the PENDULUM Mono and PENDULUM Registries ―
title_full Changes in Antithrombotic Therapy Over Time and Durability of a Prasugrel WOEST-Like Regimen for Percutaneous Coronary Intervention Patients With Atrial Fibrillation ― Post Hoc Analysis of the PENDULUM Mono and PENDULUM Registries ―
title_fullStr Changes in Antithrombotic Therapy Over Time and Durability of a Prasugrel WOEST-Like Regimen for Percutaneous Coronary Intervention Patients With Atrial Fibrillation ― Post Hoc Analysis of the PENDULUM Mono and PENDULUM Registries ―
title_full_unstemmed Changes in Antithrombotic Therapy Over Time and Durability of a Prasugrel WOEST-Like Regimen for Percutaneous Coronary Intervention Patients With Atrial Fibrillation ― Post Hoc Analysis of the PENDULUM Mono and PENDULUM Registries ―
title_short Changes in Antithrombotic Therapy Over Time and Durability of a Prasugrel WOEST-Like Regimen for Percutaneous Coronary Intervention Patients With Atrial Fibrillation ― Post Hoc Analysis of the PENDULUM Mono and PENDULUM Registries ―
title_sort changes in antithrombotic therapy over time and durability of a prasugrel woest-like regimen for percutaneous coronary intervention patients with atrial fibrillation ― post hoc analysis of the pendulum mono and pendulum registries ―
topic Original article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9072101/
https://www.ncbi.nlm.nih.gov/pubmed/35600719
http://dx.doi.org/10.1253/circrep.CR-22-0032
work_keys_str_mv AT nakaokoichi changesinantithrombotictherapyovertimeanddurabilityofaprasugrelwoestlikeregimenforpercutaneouscoronaryinterventionpatientswithatrialfibrillationposthocanalysisofthependulummonoandpendulumregistries
AT kadotakazushige changesinantithrombotictherapyovertimeanddurabilityofaprasugrelwoestlikeregimenforpercutaneouscoronaryinterventionpatientswithatrialfibrillationposthocanalysisofthependulummonoandpendulumregistries
AT nakagawayoshihisa changesinantithrombotictherapyovertimeanddurabilityofaprasugrelwoestlikeregimenforpercutaneouscoronaryinterventionpatientswithatrialfibrillationposthocanalysisofthependulummonoandpendulumregistries
AT shitejunya changesinantithrombotictherapyovertimeanddurabilityofaprasugrelwoestlikeregimenforpercutaneouscoronaryinterventionpatientswithatrialfibrillationposthocanalysisofthependulummonoandpendulumregistries
AT yokoihiroyoshi changesinantithrombotictherapyovertimeanddurabilityofaprasugrelwoestlikeregimenforpercutaneouscoronaryinterventionpatientswithatrialfibrillationposthocanalysisofthependulummonoandpendulumregistries
AT kozumaken changesinantithrombotictherapyovertimeanddurabilityofaprasugrelwoestlikeregimenforpercutaneouscoronaryinterventionpatientswithatrialfibrillationposthocanalysisofthependulummonoandpendulumregistries
AT tanabekengo changesinantithrombotictherapyovertimeanddurabilityofaprasugrelwoestlikeregimenforpercutaneouscoronaryinterventionpatientswithatrialfibrillationposthocanalysisofthependulummonoandpendulumregistries
AT akasakatakashi changesinantithrombotictherapyovertimeanddurabilityofaprasugrelwoestlikeregimenforpercutaneouscoronaryinterventionpatientswithatrialfibrillationposthocanalysisofthependulummonoandpendulumregistries
AT shinketoshiro changesinantithrombotictherapyovertimeanddurabilityofaprasugrelwoestlikeregimenforpercutaneouscoronaryinterventionpatientswithatrialfibrillationposthocanalysisofthependulummonoandpendulumregistries
AT uenotakafumi changesinantithrombotictherapyovertimeanddurabilityofaprasugrelwoestlikeregimenforpercutaneouscoronaryinterventionpatientswithatrialfibrillationposthocanalysisofthependulummonoandpendulumregistries
AT hirayamaatsushi changesinantithrombotictherapyovertimeanddurabilityofaprasugrelwoestlikeregimenforpercutaneouscoronaryinterventionpatientswithatrialfibrillationposthocanalysisofthependulummonoandpendulumregistries
AT uemurashiro changesinantithrombotictherapyovertimeanddurabilityofaprasugrelwoestlikeregimenforpercutaneouscoronaryinterventionpatientswithatrialfibrillationposthocanalysisofthependulummonoandpendulumregistries
AT haradaatsushi changesinantithrombotictherapyovertimeanddurabilityofaprasugrelwoestlikeregimenforpercutaneouscoronaryinterventionpatientswithatrialfibrillationposthocanalysisofthependulummonoandpendulumregistries
AT kurodatakeshi changesinantithrombotictherapyovertimeanddurabilityofaprasugrelwoestlikeregimenforpercutaneouscoronaryinterventionpatientswithatrialfibrillationposthocanalysisofthependulummonoandpendulumregistries
AT takitaatsushi changesinantithrombotictherapyovertimeanddurabilityofaprasugrelwoestlikeregimenforpercutaneouscoronaryinterventionpatientswithatrialfibrillationposthocanalysisofthependulummonoandpendulumregistries
AT iijimaraisuke changesinantithrombotictherapyovertimeanddurabilityofaprasugrelwoestlikeregimenforpercutaneouscoronaryinterventionpatientswithatrialfibrillationposthocanalysisofthependulummonoandpendulumregistries
AT murakamiyoshitaka changesinantithrombotictherapyovertimeanddurabilityofaprasugrelwoestlikeregimenforpercutaneouscoronaryinterventionpatientswithatrialfibrillationposthocanalysisofthependulummonoandpendulumregistries
AT saitoshigeru changesinantithrombotictherapyovertimeanddurabilityofaprasugrelwoestlikeregimenforpercutaneouscoronaryinterventionpatientswithatrialfibrillationposthocanalysisofthependulummonoandpendulumregistries
AT nakamuramasato changesinantithrombotictherapyovertimeanddurabilityofaprasugrelwoestlikeregimenforpercutaneouscoronaryinterventionpatientswithatrialfibrillationposthocanalysisofthependulummonoandpendulumregistries